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Abstract
Background: Offspring of women with diabetes in pregnancy are at increased risk of type 2 diabetes mellitus (T2DM),
potentially mediated by epigenetic mechanisms. The adipokines leptin, adiponectin, and resistin (genes: LEP, ADIPOQ,
RETN) play key roles in the pathophysiology of T2DM. We hypothesized that offspring exposed to maternal diabetes
exhibit alterations in epigenetic regulation of subcutaneous adipose tissue (SAT) adipokine transcription.
We studied adipokine plasma levels, SAT gene expression, and DNA methylation of LEP, ADIPOQ, and RETN in
adult offspring of women with gestational diabetes (O-GDM, N = 82) or type 1 diabetes (O-T1DM, N = 67) in
pregnancy, compared to offspring of women from the background population (O-BP, N = 57).
Results: Compared to O-BP, we found elevated plasma leptin and resistin levels in O-T1DM, decreased gene
expression of all adipokines in O-GDM, decreased RETN expression in O-T1DM, and increased LEP and ADIPOQ
methylation in O-GDM. In multivariate regression analysis, O-GDM remained associated with increased ADIPOQ
methylation and decreased ADIPOQ and RETN gene expression and O-T1DM remained associated with decreased RETN
expression after adjustment for potential confounders and mediators.
Conclusions: In conclusion, offspring of women with diabetes in pregnancy exhibit increased ADIPOQ DNA methylation
and decreased ADIPOQ and RETN gene expression in SAT. However, altered methylation and expression levels were not
reflected in plasma protein levels, and the functional implications of these findings remain uncertain.
Keywords: Epigenetics, Methylation, Diabetes, Pregnancy, Gestational diabetes, Fetal programming
Background
Early-life exposures may cause persisting changes in off-
spring metabolism, a concept known as fetal programming
[1–3]. Offspring of women with diabetes in pregnancy have
an increased risk of obesity, metabolic syndrome, and type
2 diabetes mellitus (T2DM) [1, 2, 4–6]. The risk appears
higher than can be explained by genetics [7, 8], implicating
a key role for the intrauterine environment. The molecular
mechanisms underlying transmission of diabetes risk from
mother to offspring are unknown, but may involve modu-
lation of circulating adipokines, which are hormones se-
creted by adipose tissue. Leptin (gene: LEP), adiponectin
(gene: ADIPOQ), and resistin (gene: RETN) are candidate
adipokines for investigation of metabolic diseases, as all
three are involved in regulation of metabolism, appetite,
and insulin sensitivity [9]. High leptin levels are associated
with obesity, insulin resistance, and metabolic syndrome,
and conversely elevated plasma adiponectin levels are asso-
ciated with decreased risk of T2DM [10, 11], while associa-
tions for resistin are contradictory [11–14].
The changes in offspring metabolism induced by expos-
ure to a detrimental fetal environment are thought to be
mediated partly by epigenetic mechanisms, with DNA
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methylation being the best understood of these mecha-
nisms [15]. Targeted and global epigenetic changes, in-
cluding changes in methylation of genes encoding
adipokines, have been reported in placenta (a central
organ in the flux of nutrition from mother to fetus, im-
portant for mediating the impact of maternal GDM) and
cord blood from newborn offspring in response to pre-
natal exposure to maternal obesity, hyperglycemia, and
GDM [16–27], but the extent to which these changes per-
sist into adulthood is unknown. Studies of the association
between maternal glycemia or BMI and offspring adipo-
kine methylation have rendered contradictory results,
showing decreased LEP and ADIPOQ methylation on the
fetal side of the placenta with increasing maternal blood
glucose concentrations [17, 18] or increased placental LEP
DNA methylation with exposure to gestational diabetes
mellitus (GDM) and maternal obesity [23]. Results on
RETN methylation are lacking, as are studies of adipokine
methylation in adulthood.
The aim of our study was to investigate whether expos-
ure to maternal diabetes causes changes in methylation
and gene expression in these adipokines, with correspond-
ing changes in plasma levels, and thereby to test the
hypothesis that epigenetic mechanisms controlling adipo-
kine gene expression and secretion are involved in the fetal
programming of T2DM.
We measured adipokine plasma levels, gene expression,
and DNA methylation in subcutaneous adipose tissue
(SAT) in a unique cohort of adult offspring of women with
either GDM or type 1 diabetes mellitus (T1DM) in preg-
nancy, compared to control offspring of women from the
background population.
Methods
Study design
The study was an observational follow-up of adult off-
spring of women with diabetes. Details of the study de-
sign, maternal inclusion criteria. and baseline data have
been described previously [5, 6, 28]. The original cohort
consisted of 1066 adult offspring born between 1978 and
1985 at Rigshospitalet, Denmark. All offspring born to
women with either GDM or T1DM, or to women from
the background population in this period, were invited
(Fig. 1). The participants in this study were between 26
and 35 years old. Of the 597 eligible offspring from the
first cross-sectional study, 456 were eligible for partici-
pation in this round of follow-up.
Participants belonged to one of three groups depending
on exposure to maternal diabetes: offspring of women with
diet-treated gestational diabetes (O-GDM, N = 82), off-
spring of women with type 1 diabetes (O-T1DM, N = 67),
and offspring of women from the background population
(O-BP, N = 57). Of the 456 eligible offspring from the sec-
ond follow-up, a total of 45% (49% O-GDM, 42% O-
T1DM, and 45% O-BP) participated in this round of
follow-up, and there was no inter-group difference in par-
ticipation rate (p = 0.445).
The study was in accordance with the Declaration of
Helsinki, approved by the regional ethical committee
(ref. nr. H-4-2011-156). All participants received written
and oral information and provided written consent be-
fore participation.
Maternal selection criteria and diabetes in pregnancy
in 1978–1985
GDM screening was based on risk factors as per clinical
procedure during the period of 1978–1985, and a diag-
nostic 3-h 50-g oral glucose tolerance test (OGTT) was
performed in the presence of one or more risk factors
and fasting blood glucose ≥4.1 mmol/l [29, 30].
T1DM mothers fulfilled the following criteria: (1) on-
set of diabetes ≤40 years of age, (2) a classical disease
history of hyperglycemic symptoms before diagnosis,
and (3) insulin treatment initiated 6 months or less after
diagnosis. In the baseline period, HbA1C measurement
was not clinical routine, and the procedure for T1DM
pregnancies involved hospitalization in the first and
third trimesters with measurement of blood glucose
seven times a day for 3 days. Mean glucose values were
calculated from these 3-day profiles.
Mothers from the background population were
unselected women routinely referred for antenatal
care and delivery at Rigshospitalet between 1978 and
1985 [6].
Examination of offspring at follow-up
Participants were recruited and examined between May
2012 and September 2013. They underwent SAT and
skeletal muscle biopsies (only the SAT biopsies were
used for this study), an OGTT, anthropometric and clin-
ical measurements, and a dual x-ray absorptiometry
(DEXA) scan [28].
Tissue samples
Biopsies were obtained through a small skin incision
under local anesthesia from abdominal SAT using a Berg-
ström needle prior to the OGTT. A total of 70–300 mg
tissue was obtained, which was immediately frozen and
stored at −80 °C until analysis.
SAT biopsies were declined or failed in 11 partici-
pants, resulting in a total of n = 195 SAT biopsies. An-
other 21 were lost during the purification process,
resulting in a total of n = 174 biopsies available for fur-
ther analysis. Of these, n = 161 contained a sufficient
amount of tissue and passed quality control and were
included in statistical analyses for gene expression.
Likewise, only samples containing sufficient amounts
of tissue after gene expression analyses as well as those
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passing strict quality control were included in methylation
analyses, resulting in n = 123 (LEP), n = 114 (ADIPOQ),
and n = 135 (RETN).
Outcome variables
The primary outcomes of interest were leptin, adiponec-
tin, and resistin plasma levels, gene expression, and
DNA methylation percentage (site-specific and average)
in SAT in the three different offspring groups. Further-
more, associations between maternal diabetes status
(GDM or T1DM) or maternal blood glucose levels (fast-
ing and 2-h post-OGTT glucose levels in GDM mothers
or mean first and third trimester blood glucose levels in
T1DM mothers) on the one hand and offspring adipo-
kine gene expression or DNA methylation on the other
hand were assessed.
Exposure variables
Exposure to maternal GDM or T1DM, determined by
offspring group, was the primary exposure variable. Ma-
ternal pregnancy blood glucose levels (fasting or 2-h
post OGTT blood glucose in GDM mothers and mean
blood glucose in the first or third trimester in T1DM
mothers) were also used as exposures variables in uni-
variate and multivariate regression analyses.
Fig. 1 Study design—flowchart of subjects participating and lost to follow-up. O-GDM offspring of women with gestational diabetes in pregnancy, O-
NoGDM offspring of women with risk factors for gestational diabetes but normal glucose tolerance in pregnancy, O-T1DM offspring of women with type
1 diabetes in pregnancy, O-BP offspring of women from the background population. *In the original cohort, 812 offspring were from the three groups,
O-GDM, O-T1DM, and O-BP, due to the fact that O-NoGDM (n = 254) were not invited for the second follow-up (1066 − 254 = 812)
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OGTT, anthropometric measurements, and DEXA scan
After an overnight fast, a 2-h 75-g OGTT was per-
formed and glucose tolerance status assessed according
to the 2006 World Health Organization criteria [31]. A
DEXA whole-body scanner (GE Medical Systems Lunar
Prodigy Advance, Fairfield, CT, USA) was used to assess
body composition. BF% was defined as (total fat mass/
total body mass) × 100. Weight, height, waist and hip cir-
cumference, and blood pressure were measured in dupli-
cates or triplicates, and mean values calculated.
Venous blood samples
We measured 0-, 30-, and 120-min plasma glucose, fasting
HbA1C, triglycerides, HDL and LDL cholesterol, hs-CRP,
and adipokine levels. Details regarding blood sampling
methods have been described previously [28]. Leptin, adi-
ponectin, and resistin were measured in fasting plasma
samples drawn in EDTA-coated vials with enzyme-linked
immunoassay using the Meso Scale Discovery (MSD) sin-
gleplex platform and analyzed on an MSD MESO Quick-
Plex SQ 120. The assays were diluted and performed
according to the manufacturer’s protocol, and all measure-
ments were performed in duplicates.
Adipokine gene expression in SAT
Total RNA extraction from SAT biopsies was performed
using miRNeasy Mini Kit (Qiagen). Fifty to 90 mg of SAT
tissue was used, and a total of 400 ng TNA was used for
complementary DNA (cDNA) synthesis. RNA concentra-
tions were measured using a NanoDrop ND 1000 spectro-
photometer (Thermo Scientific). The QuantiTect Reverse
Transcription Kit (Qiagen) was used for cDNA synthesis.
Primers were designed using human-specific databases
(Ensembl Genome Browser) and Universal ProbeLibrary
(Roche Applied Science, Additional file 1: Table S1), syn-
thesized by DNA Technology, and optimization was
performed before use to determine primer working con-
centrations. LEP, ADIPOQ, and RETN messenger RNA
(mRNA) levels were evaluated in duplicates using SYBR
Green Master Mix. mRNA expression was measured
by reverse transcription quantitative PCR using the
ViiA7 Real-Time PCR System (Applied Biosystems)
and normalized to the hypoxanthine-guanine phos-
phoribosyl transferase (HPRT) reference gene. Adipo-
kine gene expression was measured in 78% (161/206)
of participants.
Adipokine DNA methylation in SAT
Genomic DNA was extracted from SAT biopsies using the
QIAamp DNA Mini Kit (Qiagen). Twenty to 40 mg SAT
tissue was used, and a total of 400 ng DNA was bisulfite
converted using the EpiTect Bisulfite Kit (Qiagen). DNA
methylation was measured using pyrosequencing. PCR
and pyrosequencing primers (Additional file 1: Table S1)
were designed using the PyroMark Assay Design 2.0 soft-
ware, and pyrosequencing of PCR products was per-
formed using the PyroMark Q96 (all Qiagen). We studied
CpG sites in the promoter regions and first exon (for
RETN) of the three genes of interest. LEP promoter DNA
methylation was measured at CpG sites: −100, −95, −85,
−74, −71, −62, and −51 bp upstream from the transcrip-
tion start site (TSS). These sites were chosen as they are
located in a CpG island in the promoter region of the LEP
gene and have previously been shown to be associated
with LEP expression [32]. ADIPOQ promoter DNA
methylation was measured at CpG sites −112 and −45 bp
upstream from the TSS, chosen because they are located
in a promoter region shown to be sufficient for basal tran-
scriptional activity [33], and in a site previously found by
our group to be differentially methylated after 36 h of fast-
ing in normal-birthweight individuals compared to low-
birthweight individuals (unpublished data). RETN DNA
methylation was measured in the same sites previously
shown to be associated with gestational diabetes: −14, −1,
+6, +29, relative to the first exon [34].
Adipokine methylation degree was presented as site-
specific and average methylation.
Adipokine methylation was measured in 55–66%
(114–135/206) of participants.
Statistical analysis
Statistical analyses were performed using IBM SPSS Sta-
tistics version 22. Normally distributed data is presented
as mean (SD), while nonparametric data is presented as
geometric mean (95% confidence intervals (CI)). Differ-
ences between means and proportions were analyzed
with independent Student’s t tests or chi-square tests, re-
spectively. All comparisons were to the O-BP control
group. Forced-entry multiple regression analysis was
used to explore the independent association between
fetal exposure to diabetes and adipokine gene expression
or average DNA methylation. In model 1, we adjusted
for potential confounders (maternal prepregnancy BMI,
age at delivery, smoking status, family history of dia-
betes, and offspring gender and age at follow-up), and in
model 2, we then added potential mediators (offspring
homeostatic model assessment insulin resistance
(HOMA-IR) and total body fat % (BF%), HDL choles-
terol, waist circumference, and mean systolic and dia-
stolic blood pressure). Gene expression and plasma level
values were log transformed in regression analyses in
order to meet assumption of homoscedasticity. Correla-
tions were performed using Pearson’s correlation or
Spearman’s rank correlation for nonparametric data.
Listwise deletion was used in regression analyses; pair-
wise deletion was used in correlation analyses. A two-
sided p value <0.05 was considered significant.
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Results
Characteristics of the study population
Two hundred fifty offspring were lost to follow-up/ex-
cluded for various reasons: declined future participation
at the first round of follow-up in 2003 (n = 19, 7.6%),
several unsuccessful attempts at contact by mail/phone
(n = 94, 37.6%), declined participation (n = 88, 35.2%),
emigrated (n = 13, 5.2%), pregnancy (n = 15, 6.0%), ill-
nesses warranting exclusion, including known T1DM or
MODY (n = 12, 4.8%), traveling, working, or studying
abroad (n = 2, 0.8%), and a small group lost to follow-up
for other reasons (n = 7, 2.8%)—leaving a total of 206
participants (45.2%). A previously published dropout
analysis of subjects lost to follow-up from the first to the
second follow-up found that it was the healthiest off-
spring who participated in the second follow-up [28].
No difference in the majority of baseline and an-
thropometric data was found between the exposure
groups (O-GDM and O-T1DM) and O-BP, as previously
published [28].
Exposed offspring had higher 2-h OGTT glucose values
(O-GDM, p = 0.016; O-T1DM, p = 0.001), and O-GDM
demonstrated higher 30-min plasma glucose levels (p =
0.006) and borderline higher HbA1C levels (p = 0.076)
(Table 1).
Plasma adipokine levels
Leptin (p = 0.034) and resistin (p = 0.046) were increased
in O-T1DM compared to O-BP with no other significant
differences (Fig. 2). No significant difference between
groups was found after adjustment for potential con-
founders and mediators (Additional file 1: Table S2).
SAT adipokine expression levels
In crude analyses, the gene expression of all adipokines
was significantly lower in O-GDM compared to O-BP
(p ≤ 0.001). When comparing O-T1DM with O-BP, only
RETN expression was significantly decreased (p = 0.003)
(Fig. 3). When adjusting for confounders and mediators,
RETN expression remained significantly lower in the
two glucose-exposed groups (p ≤ 0.002) and ADIPOQ ex-
pression remained lower in O-GDM compared to O-BP
(p < 0.05) (Additional file 1: Table S3).
SAT adipokine DNA methylation
In O-GDM, DNA methylation of LEP and ADIPOQ was
significantly higher in crude analyses (p = 0.037 and p =
0.022, respectively), while no difference was found in
RETN DNA methylation. There were no significant dif-
ferences in adipokine DNA methylation when compar-
ing O-T1DM and O-BP (Fig. 4). After adjustment for
confounders and mediators, only ADIPOQ methylation
remained significantly higher in O-GDM (p < 0.05)
(Additional file 1: Table S4).
Correlations between plasma levels, gene expression, DNA
methylation, and clinical variables in the whole cohort
Leptin
In the cohort as a whole, there was a positive correlation
between LEP gene expression and plasma levels but no
correlation between LEP DNA methylation levels and
gene expression or plasma levels. Offspring clinical
markers of metabolic disease correlated positively with
leptin plasma levels and gene expression but not with
average LEP DNA methylation (Table 2).
Adiponectin
There was a positive correlation between ADIPOQ gene
expression and plasma levels, and a negative correlation
between ADIPOQ methylation and gene expression, but
no correlation between ADIPOQ DNA methylation and
plasma levels. Offspring clinical markers of metabolic
disease correlated negatively with adiponectin plasma
levels and gene expression, but positively with ADI DNA
methylation (Table 3).
Resistin
For resistin, there were no correlations between plasma
levels, gene expression, or DNA methylation. There was
a positive correlation between resistin plasma levels and
a negative correlation between RETN DNA methylation
and offspring clinical markers of metabolic disease.
There were no significant correlations with RETN gene
expression (Table 4).
When correlations between clinical variables and adi-
pokine plasma levels as well as gene expression and
average DNA methylation in SAT were explored in the
different subgroups, the same patterns were found, al-
though associations were not all statistically significant
(Additional file 1: Tables S5–S7).
Evaluating potential associations between maternal blood
glucose levels during pregnancy and offspring adipokine
plasma levels, gene expression, and DNA methylation
In univariate analyses, maternal fasting/2-h blood glu-
cose levels (for O-GDM) and maternal mean blood glu-
cose levels in the first/third trimester (for O-T1DM)
were not significantly associated with adipokine plasma
or gene expression levels. In multivariate regression ana-
lyses, ADIPOQ expression was borderline significantly
associated with maternal fasting blood glucose levels in
model 1, and this association became significant in
model 2 (p = 0.040). ADIPOQ expression levels were sig-
nificantly positively associated with mean maternal glu-
cose levels in the first trimester (p = 0.016) in model 1,
but this association was no longer significant in model 2.
Univariate analyses between maternal blood glucose
levels and offspring adipokine methylation showed a sig-
nificant positive association between maternal fasting
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blood glucose levels and LEP and ADIPOQ methylation
(LEP, p = 0.022; ADIPOQ, p = 0.050) for O-GDM. These
associations were no longer significant after adjustment
for potential confounders and mediators.
Discussion
We found no differences in plasma adipokine levels, de-
creased adipokine gene expression levels, and increased
DNA methylation of LEP and ADIPOQ in O-GDM com-
pared to O-BP. In O-T1DM, we found increased plasma
leptin and resistin levels, decreased ADIPOQ and RETN
gene expression levels, and no difference in average
DNA methylation levels compared to O-BP.
The decreased ADIPOQ expression and increased
average ADIPOQ methylation in O-GDM remained sig-
nificant after adjustment for potential confounders and
mediators, implying a role for hyperglycemia in preg-
nancy in causing these changes. Altered methylation or
gene expression levels could lead to changes in paracrine
adipokine functions that are not reflected by altered
plasma levels alone, which could explain the lack of dif-
ference in adiponectin plasma levels in O-GDM despite
altered ADIPOQ expression and DNA methylation.
Table 1 Clinical characteristics of the study cohort
O-GDM O-T1DM O-BP O-GDM vs. O-BP
p value
O-T1DM vs. O-BP
p value
N (total = 206) 82 67 57
Maternal characteristics
Pregestational BMI (kg/m2) 24.3 (5.6) 21.7 (1.9) 21.2 (3.5) <0.001 0.301
Maternal age at delivery 30.4 (5.2) 26.4 (4.7) 26.8 (4.6) <0.001 0.645
Maternal smoking status (yes/no) 22/69 (32%) 37/59 (63%) 26/45 (58%) <0.006 0.610
Family history of diabetes (yes vs. no) 26% (21/82) 25% (17/67) 16% (9/57) 0.166 0.191
Offspring anthropometric data
Age (years) 30.2 (2.1) 30.8 (2.4) 30.8 (2.4) 0.183 0.879
Gender (male) 52% (43/82) 46% (31/67) 46% (26/57) 0.429 0.942
Height (m) 1.76 (0.10) 1.74 (0.10) 1.74 (0.10) 0.481 0.676
Weight (kg) 77.8 (17.4) 78.3 (17.9) 75.3 (16.5) 0.398 0.331
Total body fat (%) 29.8% (0.1) 31.4% (0.1) 28.7% (0.1) 0.428 0.093
BMI (kg/m2) 25.2 (5.1) 26.0 (5.9) 24.6 (3.9) 0.493 0.113
Obese (BMI ≥30 kg/m2) 15% (12/82) 16% (11/67) 7% (4/57) 0.166 0.110
Waist circumference 85.0 (12.3) 84.3 (11.7) 82.0 (11.2) 0.149 0.265
Mean blood pressure—systolic (mmHg) 117 (9.1) 117 (8.8) 116 (11.9) 0.606 0.626
Mean blood pressure—diastolic (mmHg) 74 (7.43) 71 (9.02) 71.0 (7.28) 0.023 0.859
Results of OGTTa
Fasting plasma glucose (mmol/l) 5.0 (0.7) 4.9 (0.4) 4.9 (0.3) 0.245 0.381
30-min plasma glucose (mmol/l) 8.2 (1.71) 7.8 (1.65) 7.3 (1.6) 0.006 0.125
2-h plasma glucose (mmol/l) 6.0 (1.8) 6.3 (1.7) 5.3 (1.2) 0.016 0.001
HbA1C_DCCT (%) 5.4 (0.3) 5.3 (0.3) 5.3 (0.3) 0.079 0.569
Abnormal glucose tolerance (IFG, IGT, or T2DM) 13% (11/82) 13% (9/67) 5% (3/57) 0.116 0.125
HOMA-IRb 1.77 (1.56–2.02) 1.95 (1.71–2.22) 1.72 (1.47–2.02) 0.784 0.222
Plasma samplesb
Fasting insulin (pmol/l) 48.9 (43.3–55.2) 54.2 (47.9–61.4) 48.6 (41.9–56.4) 0.953 0.255
Triglycerides (mmol/l) 0.89 (0.81–0.98) 0.84 (0.76–0.93) 1.00 (0.76–1.31) 0.391 0.233
HDL cholesterol (mmol/l) 1.33 (1.26–1.41) 1.44 (1.37–1.52) 1.36 (1.26–1.48) 0.605 0.241
Data is mean (SD) or percentage, unless otherwise indicated. All comparisons are to the O-BP control group. Analysis of differences (means or proportions) between
groups was performed by independent samples t test or chi-square test, respectively. p values <0.05 are in bold
Abbreviations: BMI body mass index, HOMA-IR homeostatic model assessment insulin resistance, IFG impaired fasting glucose, IGT impaired glucose tolerance, O-BP
offspring of women from the background population, OGTT oral glucose tolerance test, O-GDM offspring of women with gestational diabetes, O-T1DM offspring of
women with type 1 diabetes, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus
aBased on 2-h 75-g OGTT and evaluated according to the WHO criteria of 2006 [31]
bData is presented as geometric mean and 95% confidence intervals
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Thus, the increased ADIPOQ methylation levels in O-
GDM may lead to changes that we are not aware of. Ma-
ternal GDM and T1DM also both remained significantly
negatively associated with RETN gene expression, but
not with RETN methylation, implying that methylation
of the sites studied here is not responsible for mediating
the changes in RETN expression associated with expos-
ure to maternal diabetes. ADIPOQ methylation and gene
expression both remained associated with maternal
GDM even after adjustment for potential confounders
and mediators.
The fact that SAT LEP DNA methylation was not con-
sistently associated with maternal or offspring factors is to
some extent in contrast to other results obtained in pla-
centa or cord blood samples of newborns [17, 22–24, 35].
The explanation for the different findings may besides age
differences be due to differences in the methylation sites
and tissues studied. One study found that 19–28% of vari-
ability in offspring LEP methylation was explained by ma-
ternal hyperglycemia, leaving the quantitatively largest
portion to be explained by other factors [17]. Maternal
fasting blood glucose levels became significantly associ-
ated with ADIPOQ gene expression after adjustment for
confounders and mediators, but the sample size in these
analyses was quite low (n = 45), and the findings could be
due to a type 1 error.
We found increased leptin and resistin plasma levels
in O-T1DM compared to O-BP, but especially for leptin,
these changes disappeared after adjustment for potential
confounders and mediators. A previous study found
hyperleptinemia in 6–13-year-old offspring of women
with GDM or T1DM [36]. These differences were atten-
uated after adjustment for offspring BMI, similar to our
findings, indicating that plasma leptin levels are deter-
mined largely by body composition. However, the lack of
consistent directional changes in plasma leptin levels
versus adipose tissue gene expression and methylation
levels is complicated by the development of leptin resist-
ance and/or impaired leptin clearance along with adipos-
ity development. Thus, it cannot be excluded that
obesity development in O-GDM and O-T1DM may have
been initiated by subtle impairments of adipose tissue
leptin production due to increased LEP DNA methyla-
tion causing impaired appetite suppression, adiposity,
and eventually a new balanced/compensated metabolic
state with normal or increased plasma leptin levels in
the face of decreased tissue gene expression levels. Fur-
thermore, adjusting for potential mediators bears a risk
of over-adjustment.
In our unique study material, the correlations between
LEP and ADIPOQ expression and plasma levels on the
one hand and offspring clinical variables on the other
hand in the cohort as a whole are meaningful from a
clinical point of view and in line with previous reports
[37, 38]. Resistin was named due to its ability to modu-
late insulin resistance, but studies of resistin associations
with clinical parameters of metabolic disease have shown
both positive and negative correlations with obesity, insu-
lin resistance, and other metabolic parameters [12–14].
Our results clearly show a positive correlation be-
tween resistin plasma levels and clinical parameters of
metabolic disease.
Fig. 2 Adipokine plasma levels. Data is geometric mean (95% CI). All
values are analyzed by independent samples t test after log
transformation. All comparisons are to the O-BP control group. Leptin:
O-GDM, N = 82; O-T1DM, N = 66; O-BP, N = 57. Adiponectin: O-GDM, N
= 82; O-T1DM, N = 67; O-BP, N = 56. Resistin: O-GDM, N = 82; O-T1DM,
N = 67; O-BP, N = 57. *p < 0.05. Black bars, O-GDM; striped bars, O-T1DM;
white bars, O-BP
Fig. 3 Adipokine gene expression levels in subcutaneous adipose
tissue. Data is geometric mean (95% CI). All values are analyzed by
independent samples t test after log transformation. All comparisons
are to the O-BP control group. Levels are relative to the hypoxanthine-
guanine phosphoribosyl transferase (HPRT) endogenous control gene.
LEP: O-GDM, N = 58; O-T1DM, N = 60; O-BP, N = 42. ADIPOQ and RETN:
O-GDM, N = 59; O-T1DM, N = 60; O-BP, N = 42. *p = 0.054, **p < 0.01,
***p < 0.001. Difference in LEP expression between O-T1DM and O-BP,
p = 0.072. Black bars, O-GDM; striped bars, O-T1DM; white bars, O-BP
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When examining the offspring groups separately, the
same pattern of associations between plasma levels, gene
expression, methylation, and metabolic parameters were
found as in the whole cohort, although attenuated.
T1DM usually presents with higher glucose values
than GDM, evidenced by the higher proportion of O-
T1DM born large for gestational age [5, 28], but differ-
ences in gene expression and methylation were generally
greater for O-GDM vs. O-BP, indicating that factors
other than intrauterine hyperglycemia may play a role in
mediating the observed differences. Maternal GDM is a
precursor of T2DM, and offspring of GDM women are
likely to be more genetically predisposed to T2DM, po-
tentially accounting for the greater differences in gene
expression. Moreover, maternal prepregnancy BMI may
play a role, as mothers with GDM are generally heavier
than mothers with T1DM, which was also the case in
our cohort [28]. Finally, postnatal lifestyle factors may
also play a role.
Study strengths and limitations
We are unaware of other studies with epigenetic, tran-
scriptomic, and proteomic data from adult offspring ex-
posed to maternal diabetes, and the availability of this
information is one of the strengths of our study. Further-
more, our study is unique due to the availability of meta-
bolically important target tissue in the relatively large
sample size. Studies analyzing adipokine methylation, ex-
pression, or plasma levels in offspring exposed to intra-
uterine hyperglycemia have mainly been performed in
placental tissues or umbilical cord blood from newborns
[16, 17, 39–41], or young children [36, 42], but tissue
a b
c d
e f
Fig. 4 Site-specific and average DNA methylation for a, b leptin, c, d adiponectin, and e, f resistin in subcutaneous adipose tissue. CpG sites are denoted
as the number of base pairs upstream (−) or downstream (+) from the transcription start sites. Data is mean ± SD and analyzed using independent
samples t test. All comparisons are to the O-BP control group. *p < 0.05, **p < 0.01. Black bars, O-GDM; striped bars, O-T1DM; white bars, O-BP
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specificity of epigenetic marks makes it difficult to ex-
trapolate these results to other tissues. The availability of
maternal blood glucose values constitutes another
strength of this study, but more sophisticated measures
of maternal glycemia such as HbA1C or home blood
glucose measurements would have been more precise in-
dicators of maternal glycemia.
Study limitations, addressed previously [28], include se-
lection bias as well as residual confounding. Twenty-five
percent of offspring from the original cohort participated
in the second round of follow-up on which this study is
based, and those lost to follow-up included the least
healthy subjects diagnosed with prediabetes, metabolic
syndrome, or T2DM already during the first follow-up, as
previously shown [28]. Although this is an important
cause of selection bias, it will tend to push towards an
underestimation of our results.
As mentioned in the “Methods” section, gene expres-
sion and methylation analyses were not measured in all
subjects. However, since different subsets were available
Table 2 Correlations between leptin plasma levels, gene expression, DNA methylation, and offspring clinical variables in the cohort
as a whole (O-GDM, O-T1DM, and O-BP combined)
Leptin plasma levels LEP gene expression Average LEP DNA methylation
Leptin plasma levels 0.594 (<0.001) 0.141 (0.120)
LEP gene expression 0.594 (<0.001) −0.001 (0.991)
Average LEP DNA methylation 0.141 (0.120) −0.001 (0.991)
BMI (kg/m2) 0.472 (<0.001) 0.279 (<0.001) 0.059 (0.519)a
Fasting insulin (pmol/l) 0.540 (<0.001) 0.303 (<0.001) 0.131 (0.163)a
Fasting plasma glucose (mmol/l) 0.082 (0.245) 0.121 (0.130) 0.152 (0.094)a
120-min plasma glucose (mmol/l) 0.267 (<0.001) 0.317 (<0.001) 0.173 (0.062)a
Total body fat (%) 0.892 (<0.001) 0.564 (<0.001) 0.126 (0.167)a
HOMA-IR 0.527 (<0.001) 0.296 (<0.001) 0.149 (0.113)a
Mean systolic blood pressure (mmHg) −0.138 (0.050) −0.127 (0.112) 0.032 (0.725)a
Mean diastolic blood pressure (mmHg) 0.368 (<0.001) 0.187 (0.019) 0.134 (0.138)a
Waist circumference (cm) 0.206 (0.003) 0.149 (0.061) 0.096 (0.289)a
HDL cholesterol (mmol/l) 0.071 (0.316) −0.008 (0.919) −0.133 (0.141)a
Data is Spearman’s rank coefficient R (p value) unless otherwise indicated. p values <0.05 are in italics
O-GDM offspring of women with gestational diabetes, O-T1DM offspring of women with type 1 diabetes, O-BP offspring of women from the background population
aPearson’s correlation coefficient
Table 3 Correlations between adiponectin plasma levels, gene expression, DNA methylation, and offspring clinical variables in the
cohort as a whole (O-GDM, O-T1DM, and O-BP combined)
Adiponectin plasma levels ADIPOQ gene expression Average ADIPOQ DNA methylation
Adiponectin plasma levels 0.169 (0.032) −0.084 (0.376)
ADIPOQ gene expression 0.169 (0.032) −0.266 (0.013)
Average ADIPOQ DNA methylation −0.084 (0.376) −0.266 (0.013)
BMI (kg/m2) −0.195 (0.005) −0.417 (<0.001) 0.359 (<0.001)a
Fasting insulin (pmol/l) −0.281 (<0.001) −0.341 (<0.001) 0.318 (0.001)a
Fasting plasma glucose (mmol/l) −0.145 (0.039) −0.163 (0.039) 0.195 (0.038)a
120-min plasma glucose (mmol/l) −0.141 (0.049) −0.063 (0.441) 0.219 (0.022)a
Total body fat (%) −0.078 (0.268) −0.164 (0.038) 0.212 (0.024)a
HOMA-IR −0.289 (<0.001) −0.360 (<0.001) 0.344(<0.001)a
Mean systolic blood pressure (mmHg) −0.195 (0.005) −0.274 (<0.001) 0.175 (0.062)a
Mean diastolic blood pressure (mmHg) −0.139 (0.048) −0.351 (<0.001) 0.148 (0.115)a
Waist circumference (cm) −0.239 (0.001) −0.439 (<0.001) 0.447 (<0.001)a
HDL cholesterol (mmol/l) 0.240 (0.001) 0.356 (<0.001) −0.286 (0.002)a
Data is Spearman’s rank coefficient R (p value) unless otherwise indicated. p values <0.05 are in italics
O-GDM offspring of women with gestational diabetes, O-T1DM offspring of women with type 1 diabetes, O-BP offspring of women from the background population
aPearson’s correlation coefficient
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for the different analyses, and as such there was no sys-
tematic selection in the population undergoing these
analyses, we do not believe this biased our results signifi-
cantly. Due to our a priori knowledge of adipose tissue
adipokines playing a major role in the development of
adiposity and associated diseases including T2DM, we
used a target candidate approach to characterize adipose
tissue DNA methylation, gene expression levels, and
circulating levels of the three major adipokines. Com-
pared with the alternative approach of applying random
DNA methylation or gene expression array approaches,
we avoided complicated statistical and bioinformatical
analyses with corrections for multiple comparisons.
Thereby, we provided compelling proof of principle of
potentially functionally important epigenetic and tran-
scriptional gene regulation changes in adipose tissue
biopsies from offspring of women with diabetes in preg-
nancy. Indeed, these findings pave the way for additional
large-scale epigenetic and transcriptional omics studies
in this unique cohort to explore additional epigenetic
mechanisms involved in programming of metabolic
disease.
Although the specific genes studied here are known to
play an important role in the pathophysiology of meta-
bolic disease [9], other cytokines, signal molecules, and
methylation sites are likely to be involved in the fetal
programming of metabolic disease. Finally, other epigen-
etic mechanisms besides methylation (e.g., miRNAs)
could also be involved in mediating adipokine expression
and function. Thus, the current study does not provide a
complete view of the metabolic pathways potentially af-
fected by exposure to maternal diabetes.
The authors wish to emphasize that the current data
were obtained in biopsies of predominantly mature adi-
pose tissue cells influenced to some unknown extent by
the ambient in vivo metabolic, endocrine and paracrine
environment. This is in contrast to another recent paper
including isolated preadipocytes in a subgroup from the
same cohort of offspring of women with and without
diabetes in pregnancy cultured during standardized and
controlled in vitro conditions [43], explaining the differ-
ential epigenetic and transcriptional findings in the two
papers.
Conclusion
Exposure to maternal GDM was associated with in-
creased ADIPOQ methylation and decreased ADIPOQ
and RETN gene expression after adjustment for potential
confounders and mediators. Especially for ADIPOQ
methylation and expression, our findings support our
original hypothesis that epigenetic mechanisms control-
ling adipokine gene expression may be involved in fetal
programming of T2DM. The decreased adipokine gene
expression levels were not reflected in plasma protein
levels, and further studies are needed to understand the
functional implications of these findings.
Additional files
Additional file 1: Figure S1. Adipokine DNA methylation sites studied.
Table S1. Primers for RT-qPCR and DNA methylation. Table S2. Adipokine
plasma levels. Table S3. Adipokine gene expression levels in subcutaneous
adipose tissue. Table S4.Average Adipokine DNA methylation levels in sub-
cutaneous
Table 4 Correlations between resistin plasma levels, gene expression, DNA methylation, and offspring clinical variables in the cohort
as a whole (O-GDM, O-T1DM, and O-BP combined)
Resistin plasma levels RETN gene expression Average RETN DNA methylation
Resistin plasma levels 0.070 (0.380) −0.162 (0.061)
RETN gene expression 0.070 (0.380) 0.109 (0.270)
Average RETN DNA methylation −0.162 (0.061) 0.109 (0.270)
BMI (kg/m2) 0.177 (0.011) −0.110 (0.165) −0.270 (0.002)a
Fasting insulin (pmol/l) 0.198 (0.007) 0.003 (0.970) −0.327 (<0.001)a
Fasting plasma glucose (mmol/l) 0.154 (0.027) −0.051 (0.523) −0.183 (0.033)a
120-min plasma glucose (mmol/l) 0.022 (0.762) 0.002 (0.977) −0.089 (0.318)a
Total body fat (%) 0.230 (0.001) −0.044 (0.577) −0.320 (<0.001)a
HOMA-IR 0.224 (0.002) −0.012 (0.883) −0.344 (<0.001)a
Mean systolic blood pressure (mmHg) 0.079 (0.262) −0.116 (0.144) −0.051 (0.555)a
Mean diastolic blood pressure (mmHg) 0.212 (0.002) −0.183 (0.021) −0.233 (0.007)a
Waist circumference (cm) 0.058 (0.409) −0.131 (0.099) −0.260 (0.002)a
HDL cholesterol (mmol/l) −0.017 (0.813) 0.016 (0.844) 0.096 (0.268)a
Data is Spearman’s rank coefficient R (p value) unless otherwise indicated. p values <0.05 are in italics
O-GDM offspring of women with gestational diabetes, O-T1DM offspring of women with type 1 diabetes, O-BP offspring of women from the background population
aPearson’s correlation coefficient
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adipose tissue. Table S5. Correlations between leptin plasma levels, gene
expression, DNA methylation and clinical variables by offspring group.
Table S6. Correlations between adiponectin plasma levels, gene expression,
DNA methylation and clinical variables by offspring group. Table S7.
Correlations between resistin plasma levels, gene expression, DNA
methylation and clinical variables by offspring group. (DOCX 63 kb)
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